Next earnings date: 12 Aug 2025
Molecular Templates, Inc. – NASDAQ:MTEM
Molecular Templates stock price today
Molecular Templates stock price monthly change
Molecular Templates stock price quarterly change
Molecular Templates stock price yearly change
Molecular Templates key metrics
Market Cap | 946.76K |
Enterprise value | 40.43M |
P/E | -0.28 |
EV/Sales | 1.23 |
EV/EBITDA | 0.62 |
Price/Sales | 0.74 |
Price/Book | -1.60 |
PEG ratio | 0.11 |
EPS | -2.69 |
Revenue | 31.52M |
EBITDA | -7.21M |
Income | -10.09M |
Revenue Q/Q | -67.03% |
Revenue Y/Y | -29.78% |
Profit margin | 142.96% |
Oper. margin | 136.96% |
Gross margin | 13.53% |
EBIT margin | 136.96% |
EBITDA margin | -22.89% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMolecular Templates stock price history
Molecular Templates stock forecast
Molecular Templates financial statements
| Jun 2023 | 6.62M | -10.86M | -164% |
|---|---|---|---|
| Sep 2023 | 6.79M | 4.15M | 61.11% |
| Dec 2023 | 7.01M | -3.94M | -56.27% |
| Mar 2024 | 11.08M | 572K | 5.16% |
| 2025 | 1.36M | -34.73M | -2541.26% |
|---|---|---|---|
| 2026 | 26.73M | -184.32M | -689.48% |
Analysts Price target
Financials & Ratios estimates
| 2024-08-14 | -1.44 | -1.23 |
|---|
| Jun 2023 | 35512000 | 44.19M | 124.44% |
|---|---|---|---|
| Sep 2023 | 44061000 | 37.26M | 84.56% |
| Dec 2023 | 35383000 | 31.17M | 88.1% |
| Mar 2024 | 27119000 | 21.24M | 78.35% |
| Jun 2023 | -9.63M | 3.13M | -27.5M |
|---|---|---|---|
| Sep 2023 | -7.53M | 9K | 18.38M |
| Dec 2023 | -5.28M | -1K | 0 |
| Mar 2024 | -5.24M | 0 | 0 |
Molecular Templates alternative data
| Aug 2023 | 111 |
|---|---|
| Sep 2023 | 111 |
| Oct 2023 | 111 |
| Nov 2023 | 111 |
| Dec 2023 | 111 |
| Jan 2024 | 111 |
| Feb 2024 | 111 |
| Mar 2024 | 111 |
| Apr 2024 | 111 |
| May 2024 | 62 |
| Jun 2024 | 62 |
| Jul 2024 | 62 |
Molecular Templates other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2024 | 1154001 | 0 |
| Nov 2024 | 0 | 1279820 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BIOTECH TARGET N V 10 percent owner | Common Stock | 1,279,820 | $0.66 | $845,961 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Common Stock | 250,000 | $2.35 | $587,500 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Common Warrants (right to buy) | 769,334 | $2.35 | $1,807,935 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Prefunded Warrants (right to buy) | 134,667 | $0 | $135 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Common Stock | 4,255,319 | $0.47 | $2,000,000 | ||
Option | KIM JASON S. officer: See remarks | Stock Option (right to buy) | 12,089 | $0.71 | $8,583 | ||
Option | KIM JASON S. officer: See remarks | Common Stock | 12,089 | $0.71 | $8,583 | ||
Purchase | MCLENNAN SEAN officer: See remarks | Common Stock | 30,000 | $0.82 | $24,480 | ||
Purchase | BIOTECH TARGET N V 10 percent owner | Common Stock | 200,000 | $1.18 | $236,200 | ||
Option | POMA ERIC E director, officer.. | Stock Option (right to buy) | 27,325 | $0.71 | $19,401 |
-
What's the price of Molecular Templates stock today?
One share of Molecular Templates stock can currently be purchased for approximately $0.
-
When is Molecular Templates's next earnings date?
Molecular Templates, Inc. is estimated to report earnings on Tuesday, 12 Aug 2025.
-
Does Molecular Templates pay dividends?
No, Molecular Templates does not pay dividends.
-
How much money does Molecular Templates make?
Molecular Templates has a market capitalization of 946.76K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 190.1% to 57.31M US dollars. Molecular Templates made a loss 8.12M US dollars in net income (profit) last year or -$1.23 on an earnings per share basis.
-
What is Molecular Templates's stock symbol?
Molecular Templates, Inc. is traded on the NASDAQ under the ticker symbol "MTEM".
-
What is Molecular Templates's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Molecular Templates?
Shares of Molecular Templates can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Molecular Templates's key executives?
Molecular Templates's management team includes the following people:
- Dr. Eric E. Poma Chief Executive Officer, Chief Scientific Officer & Director(age: 53, pay: $820,900)
- Ms. Jason S Kim Pres & Chief Operating Officer(age: 50, pay: $590,250)
- Dr. Roger J. Waltzman Chief Medical Officer(age: 57, pay: $572,910)
-
How many employees does Molecular Templates have?
As Jul 2024, Molecular Templates employs 62 workers, which is 44% less then previous quarter.
-
When Molecular Templates went public?
Molecular Templates, Inc. is publicly traded company for more then 20 years since IPO on 4 Feb 2005.
-
What is Molecular Templates's official website?
The official website for Molecular Templates is mtem.com.
-
Where are Molecular Templates's headquarters?
Molecular Templates is headquartered at 9301 Amberglen Boulevard, Austin, TX.
-
How can i contact Molecular Templates?
Molecular Templates's mailing address is 9301 Amberglen Boulevard, Austin, TX and company can be reached via phone at +51 28691555.
Molecular Templates company profile:
Molecular Templates, Inc.
mtem.comNASDAQ
62
Biotechnology
Healthcare
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Austin, TX 78729
CIK: 0001183765
ISIN: US6085502085
CUSIP: 608550109
